GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Shiller PE Ratio

International Stem Cell (International Stem Cell) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


International Stem Cell Shiller PE Ratio Historical Data

The historical data trend for International Stem Cell's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Shiller PE Ratio Chart

International Stem Cell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

International Stem Cell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of International Stem Cell's Shiller PE Ratio

For the Biotechnology subindustry, International Stem Cell's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Shiller PE Ratio falls into.



International Stem Cell Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

International Stem Cell's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, International Stem Cell's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.03/131.7762*131.7762
=-0.030

Current CPI (Mar. 2024) = 131.7762.

International Stem Cell Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -3.885 100.560 -5.091
201409 -1.400 100.428 -1.837
201412 -3.810 99.070 -5.068
201503 -1.070 99.621 -1.415
201506 -0.520 100.684 -0.681
201509 -0.280 100.392 -0.368
201512 -0.720 99.792 -0.951
201603 -5.190 100.470 -6.807
201606 0.260 101.688 0.337
201609 -0.300 101.861 -0.388
201612 0.547 101.863 0.708
201703 -0.780 102.862 -0.999
201706 -0.250 103.349 -0.319
201709 -0.540 104.136 -0.683
201712 -0.290 104.011 -0.367
201803 -0.140 105.290 -0.175
201806 -0.060 106.317 -0.074
201809 0.020 106.507 0.025
201812 -0.150 105.998 -0.186
201903 -0.120 107.251 -0.147
201906 -0.090 108.070 -0.110
201909 0.000 108.329 0.000
201912 -0.360 108.420 -0.438
202003 -0.050 108.902 -0.061
202006 -0.140 108.767 -0.170
202009 -0.070 109.815 -0.084
202012 -0.090 109.897 -0.108
202103 -0.080 111.754 -0.094
202106 0.030 114.631 0.034
202109 -0.020 115.734 -0.023
202112 -0.040 117.630 -0.045
202203 -0.001 121.301 -0.001
202206 0.000 125.017 0.000
202209 -0.040 125.227 -0.042
202212 0.000 125.222 0.000
202303 -0.004 127.348 -0.004
202306 0.030 128.729 0.031
202309 -0.020 129.860 -0.020
202312 -0.040 129.419 -0.041
202403 -0.030 131.776 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


International Stem Cell  (OTCPK:ISCO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


International Stem Cell Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


International Stem Cell (International Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027